VRXA Stock Chart & Stats
$1.35
>-$0.01(-0.04%)
At close: 4:00 PM EST
$1.35
>-$0.01(-0.04%)
Day’s Range― - ―
52-Week Range$1.27 - $27.36
Previous CloseN/A
VolumeN/A
Average Volume (3M)303.28K
Market Cap
$243.76M
Enterprise Value$303.88M
Total Cash (Recent Filing)$32.79K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)50.8
Beta0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding141,407,800
10 Day Avg. Volume646,716
30 Day Avg. Volume303,278
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.05
Price to Sales (P/S)0.00
P/FCF Ratio-555.25
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-81.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Veraxa Biotech News
VRXA FAQ
What was Veraxa Biotech’s price range in the past 12 months?
Veraxa Biotech lowest stock price was $1.27 and its highest was $27.36 in the past 12 months.
What is Veraxa Biotech’s market cap?
Veraxa Biotech’s market cap is $243.76M.
When is Veraxa Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Veraxa Biotech’s earnings last quarter?
Currently, no data Available
Is Veraxa Biotech overvalued?
According to Wall Street analysts Veraxa Biotech’s price is currently Overvalued.
Does Veraxa Biotech pay dividends?
Veraxa Biotech does not currently pay dividends.
What is Veraxa Biotech’s EPS estimate?
Veraxa Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Veraxa Biotech have?
Veraxa Biotech has 141,407,800 shares outstanding.
What happened to Veraxa Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Veraxa Biotech?
Currently, no hedge funds are holding shares in VRXA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veraxa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $82.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Veraxa Biotech
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Technical Analysis
Inmune Bio
―
Pliant Therapeutics
―
TScan Therapeutics
―
MiNK Therapeutics
―
Xilio Therapeutics
―
Ownership Overview
4.09% Insiders
0.83% Mutual Funds
0.12% Other Institutional Investors
94.94% Public Companies and
Individual Investors